Insider buying last 90 days
No open-market insider purchases were filed for LKFT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LKFT insider filing, plotted on the chart in Gekko.Open LKFT in Gekko
Gekko Brief
AI summaryOct 12 closeThis week's news for Lakefront Biotherapeutics (LKFT) centers on ownership and buyback activity rather than operating results. Bank of America disclosed a reduction in its stake, crossing below the 10% threshold to 8.54% of voting rights as of October 2, 2026, while separate notices detail the company's ongoing share repurchase program, including 117,437 shares bought back between September 28 and October 2, 2026 at an average price of €25.99, for a total of €3,051,866.51.
Shares closed at $29.57, down 0.5%, sitting between the 50-day average of $28.47 and the 200-day average of $30.21. The GekkoIndex reads 57, placing the stock in the Neutral zone, up 1.1 over five days. Price remains 18% below Gekko Fair Value of $36.07, a gap that stands out against a generally mixed trend picture, with one-month returns at 10.3% but one-year returns at -14.1%.
The next earnings date falls on 11 November 2026, 29 days out and beyond a typical 20-trading-day hold; the prior report on 10 August 2026 saw a 6.4% reaction versus an average absolute move of 4.2%, with 4 beats across 7 quarters. No insider, Congress, or unusual options activity appears in the respective windows. Seasonally, the next 20 trading days have averaged a 1.3% gain over 5 years, rising in 2 of them. Two analysts cover the stock, split between buy and hold, with a consensus target of $30.24.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Galapagos price vs fair value
Close $29.57200-day averageGekko Fair Value $36.07
Galapagos quick facts
- Market cap
- $1.95B
- P/E ratio
- 2.8
- Forward P/E
- 344.8
- EPS, TTM
- $10.52
- Revenue, TTM
- $990.6M
- Profit margin
- 60.2%
- Dividend yield
- —
- Beta
- 0.06
- Volume
- 220,246 avg 380,585
- 1-year return
- −14.1%
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±6%
- 50-day average
- $28.47
- 200-day average
- $30.21
- Next earnings
- Nov 11
- Shares outstanding
- 65.49M
Galapagos swing-trade checklist
Galapagos scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
- Trendmixed
Averages disagree
Close $29.57 sits between the 50-day ($28.47) and 200-day ($30.21) averages, or the averages disagree.
See the chart - GekkoIndexmixed
57, Neutral
Reading 57 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
18.0% below
Price is 18% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Galapagos stock chart and price history
Galapagos closed at $29.57 on Oct 12, 2026, −14.1% over the past year, inside a 52-week range of $25.68 to $37.78.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +10.3%
- 3 months
- −0.1%
- 6 months
- −1.4%
- 1 year
- −14.1%
The full LKFT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LKFT in Gekko
Follow Galapagos through every session
Put LKFT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LKFT in GekkoFree for 7 days. No credit card required.
About Galapagos
Galapagos, now operating as Lakefront Biotherapeutics NV, is a biotechnology company working to improve outcomes for patients through scientific research. Its efforts center on developing new medicines for serious illnesses where treatment options remain limited, with particular attention to oncology and to immunology and inflammation. The company has become known for its work on potential first-in-class therapies aimed at autoimmune conditions.
Its portfolio is built around a pipeline of clinical-stage programs rather than approved products already on the market. The emphasis falls on addressing diseases where existing treatments fall short, positioning its research toward patients whose medical needs are not yet well served.
Galapagos trades under the ticker LKFT.
- Sector
- Health technology
- Website
- lakefrontbio.com
Galapagos GekkoIndex: the smart money zone
Galapagos’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, up 1.1 points over five sessions.
57Neutral
Up 1.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 86 | +0.3% | +2.4% | ||
| Accumulation | 177 | +0.3% | +0.8% | ||
| Neutral (current zone) | 347 | −0.1% | −0.7% | ||
| Distribution | 17 | −1.2% | −3.1% | ||
| Selling | 0 | Not available | |||
Average LKFT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the LKFT price, zone by zone.Track LKFT in Gekko
Is Galapagos stock overvalued? Gekko Fair Value
Galapagos trades 18.0% below Gekko Fair Value of $36.07, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Galapagos shares are worth, recalculated every trading day.
$36.07
Gekko Fair Value, Oct 10, 2026
18.0% Undervalued
At the end of Aug 2026 the price was 22.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LKFT in Gekko
Galapagos insider and Congress trading
No open-market insider purchases were filed for Galapagos, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LKFT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LKFT, plotted on the chart in Gekko.Open LKFT in Gekko
Hedge funds and billionaires quarter ended Sep 30
2of the funds Gekko tracks hold LKFT.
2added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Galapagos earnings: next date and track record
Galapagos reports on Nov 11, 2026 (30 days away), and beat the EPS estimate in 4 of its last 7 reports.
Next earnings report
Nov 11, 2026
30 days away
- EPS estimate
- −$0.83
- Revenue estimate
- $7.50M
4 of 7reports beat the EPS estimate
±4.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | $0.03 est −$11.50 | $14.03M est $13.99M | +6.4% |
| May 6, 2026 | $0.21 est −$0.97 | $7.63M est $9.59M | −2.3% |
| Feb 23, 2026 | $12.27 est −$0.07 | $1.05B est $82.87M | +1.7% |
| Nov 5, 2025 | −$3.59 est −$0.20 | $83.35M est $80.10M | +2.4% |
| Jul 23, 2025 | −$0.93 est −$0.13 | $76.82M est $80.08M | −5.9% |
| Apr 23, 2025 | $0.97 est −$0.18 | $85.28M est $71.90M | +5.6% |
| Feb 13, 2025 | $0.41 | $79.31M est $76.97M | +1.9% |
| Oct 30, 2024 | −$0.74 est −$0.12 | $65.64M est $78.21M | −7.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Galapagos stock forecast and analyst price targets
Analysts’ average 12-month price target for Galapagos is $30.24, +2.3% from the last close, from 2 firms rating the stock in the last 90 days.
$30.24consensus 12-month target, +2.3% from the last close
Now $29.57Avg $30.24
Low $26High $45
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Morgan Stanley | $26 | −12.1% |
| Sep 28 | Morgan Stanley | $26 | −12.1% |
| Sep 23 | RBC Capital | $45 | +52.2% |
| Sep 21 | Morgan Stanley | $26 | −12.1% |
| Aug 31 | Morgan Stanley | $26 | −12.1% |
−0.7%average 20-day move after past Neutral readings
+1.3%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Galapagos seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Galapagos averaged +1.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.5% | 4 of 5 |
| Next 10 trading days | +0.7% | 3 of 5 |
| Next 15 trading days | +0.9% | 2 of 5 |
| Next 20 trading days | +1.3% | 2 of 5 |
| Next 30 trading days | −4.3% | 1 of 5 |
For scale, LKFT’s typical 20-trading-day move in either direction is about 6%.
Galapagos market cap and key statistics
Galapagos’s market cap is $1.95B, with a P/E ratio of 2.8 and revenue of $990.6M over the last twelve months.
Valuation
- Market cap
- $1.95B
- P/E ratio
- 2.8
- Forward P/E
- 344.8
- EPS, TTM
- $10.52
- Gekko Fair Value
- $36.07
Trading
- Volume
- 220,246
- Avg volume, 20 days
- 380,585
- 52-week high
- $37.78
- 52-week low
- $25.68
- Shares outstanding
- 65.49M
Financials
- Revenue, TTM
- $990.6M
- Profit margin
- 60.2%
- Return on equity
- 20.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.06
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±6%
Galapagos stock news this week
Coverage of Galapagos this week reads neutral: 0 positive, 2 neutral and 1 negative headlines.
- Lakefront Biotherapeutics NV (LKFT.AS) latest press releases and corporate newsYahoo Finance UK, Oct 10
- Bank of America crosses below 10% in Lakefront Biotherapeutics (LKFT) after disposals.Stock Titan, Oct 8
- At €25.99 a share, Lakefront Biotherapeutics (LKFT) repurchased €3.05M of its stock.Stock Titan, Oct 7
Galapagos stock FAQ
What is Galapagos’s market cap?
Galapagos’s market cap is $1.95B at the Oct 12, 2026 close of $29.57, with 65.49M shares outstanding. The shares trade on a P/E ratio of 2.8.
What is the Galapagos stock forecast?
The consensus analyst 12-month price target for Galapagos is $30.24, +2.3% from the last close. Of the 2 firms that rated the stock in the last 90 days, 1 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Galapagos stock overvalued or undervalued?
On Gekko’s estimate Galapagos is undervalued: the Oct 12, 2026 close of $29.57 is 18.0% below Gekko Fair Value of $36.07. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Galapagos report earnings next?
Galapagos is expected to report on Nov 11, 2026 (30 days away). Analysts expect earnings of −$0.83 per share on revenue of $7.50M. Galapagos beat the earnings estimate in 4 of its last 7 reports, moving 4.2% on average across the report.
What is Galapagos’s 52-week high and low?
Galapagos’s 52-week high is $37.78 and its 52-week low is $25.68; it closed at $29.57 on Oct 12, 2026, −14.1% over the past year. Over the last five years the shares peaked at $72.11 on Apr 7, 2022.
Is Galapagos stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 3 as mixed (trend, gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Galapagos the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.